Publications in collaboration with researchers from Beckman Research Institute (23)

2024

  1. AI is a viable alternative to high throughput screening: a 318-target study

    Scientific Reports, Vol. 14, Núm. 1

  2. Correction to: AI is a viable alternative to high throughput screening: a 318-target study (Scientific Reports, (2024), 14, 1, (7526), 10.1038/s41598-024-54655-z)

    Scientific Reports

  3. Multidisciplinary Delphi Consensus on Safety of Combining Transarterial Radioembolization with Yttrium-90 Microspheres with Systemic Anticancer Agents for the Treatment of Liver Malignancy

    Journal of Vascular and Interventional Radiology, Vol. 35, Núm. 9, pp. 1253-1267.e1

  4. Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia

    American Journal of Hematology, Vol. 99, Núm. 4, pp. 586-595

2023

  1. Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer

    Nature Communications, Vol. 14, Núm. 1

  2. Plain language summary of the MonumenTAL-1 study of talquetamab in people with relapsed or refractory multiple myeloma

    Future Oncology, Vol. 19, Núm. 27, pp. 1823-1840

2022

  1. IBCL-249 Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients With Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results From a Phase I/II Study

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S387

  2. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study

    The Lancet Oncology, Vol. 23, Núm. 8, pp. 1055-1065

2021

  1. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  2. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials

    Leukemia, Vol. 35, Núm. 1, pp. 18-30

  3. The importance of low-dose CT screening to identify emphysema in asymptomatic participants with and without a prior diagnosis of COPD

    Clinical Imaging, Vol. 78, pp. 136-141

2020

  1. Key components of a hepatobiliary surgery curriculum for general surgery residents: results of the FULCRUM International Delphi consensus

    HPB, Vol. 22, Núm. 10, pp. 1429-1441

2017

  1. Safety of selective internal radiation therapy (SIRT) with yttrium-90 microspheres combined with systemic anticancer agents: Expert consensus

    Journal of Gastrointestinal Oncology, Vol. 8, Núm. 6, pp. 1079-1099

2016

  1. Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies

    Cancer, Vol. 122, Núm. 14, pp. 2178-2185

  2. Impact of surgery for stage IA non-smallcell lung cancer on patient quality of life

    Journal of Community and Supportive Oncology, Vol. 14, Núm. 1, pp. 37-44

  3. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

    Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557

2015

  1. Analysis of heritability and shared heritability based on genome-wide association studies for thirteen cancer types

    Journal of the National Cancer Institute, Vol. 107, Núm. 12

2014

  1. Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33

    Human Molecular Genetics, Vol. 23, Núm. 24, pp. 6616-6633

2010

  1. An increase in compliance with the surgical care improvement project measures does not prevent surgical site infection in colorectal surgery

    Diseases of the Colon and Rectum, Vol. 53, Núm. 1, pp. 24-30

  2. Validation of the risk index category as a predictor of surgical site infection in elective colorectal surgery

    Diseases of the Colon and Rectum, Vol. 53, Núm. 5, pp. 721-727